Description of ATRIANCE (Nelarabine) Injection
Atriance is a solution for infusion. It contains the active substance Nelarabine.
Atriance is used to treat patients with Lymphoblastic Leukemia
Its use and Indications
Atriance is indicated for the treatment of patients with T-cell acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
Treatment related information
For treatment related information, please consult your treating Physician.
Atriance is supplied as 5mg/ml solution for infusion. The pack strength is 250 mg /50 ml, and is supplied in a pack of 6 vials
Storage and handling
Stable for up to 8 hours at up to 30° C, once the vial is opened
How do we source the Drug?
Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is also essential.
Company that Manufactures/ Markets:
M/s GlaxoSmithKline (GSK)
Mob No: +91 7738100125, +91 7738151650
E Mail: firstname.lastname@example.org